Vaccine Safety Screening For Adventitious Agents Looms Large At Substrates Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Vaccine and Related Biological Products Advisory Committee will examine the role of emerging technologies for detecting adventitious agents in assessing whether novel human tumor-derived cell-line substrates are suitable for vaccine production.
You may also be interested in...
Vaccine Manufacturers Need Plans To Cut Adventitious Agents By October
FDA is sending two rounds of letters to different sets of companies asking for the plans as part of the fall-out from the issues seen in rotavirus vaccines.
Vaccines Face Unknown Contamination Risks, But Need Well-Defined Testing
The discovery of adventitious porcine virus in Merck's RotaTeq and GlaxoSmithKline's Rotarix is setting off a scramble among vaccine manufacturers and FDA to come up with validated procedures to detect and deal with such undesirable agents
Porcine Virus In Merck's RotaTeq Raises Questions Of Timing, Testing
Revealed on the eve of an advisory committee meeting about safety of GSK's rival vaccine Rotarix, finding suggests that FDA and industry have considerable work to do on viral testing techniques.